The ICAReB Platform: A Human Biobank for the Institut Pasteur and Beyond

Abstract

The ICAReB platform of Institut Pasteur provides access to human bio-resources for academic and private research teams worldwide, essentially in the fields of infection, immunity and neurosciences. More than 134,000 human quality controlled, duly annotated samples (mainly whole-blood derived products, but also stool, urine, saliva, swabs….), from both healthy and diseased cohorts with open, regulated access, are available upon request. Both clinical investigation and biobanking activities are certified following ISO 9001:2015 and NF S96-900:2011 standards, respectively. ICAReB is a member of PIBnet (Pasteur International Biobanking network), BIOBANQUES and BBMRI, the French and pan-european biobanking networks, respectively. Funding statement: Funds come from IP (facilities and staff), and from various funding organisms or agencies (for specific projects): ANR (French National Research funding Agency): OH!Ticks project (see https://www.ohticks.fr/ 2017–2020) AP/HP (Assistance Publique/Hopitaux de Paris): MonaLisa (Multicentric Observational National Analysis on Listeriosis and Listeria) and ListeriaGEN projects, 2009–2022 and 2015–2024, respectively AVIESAN (French National alliance for Life Sciences and Health). Study of the innate immunity and the microbial flora during aplasia (PAMPA project, 2013–2016) Bioaster (French Investissements d’Avenir funding, Infectiology and Microbiology platform, Lyon-Paris, 2010–2020) Biomerieux (Lyon, France; cardio-vascular biomarker, 2013–2015) FRM (Medical Research Foundation): Hidradenitis Suppurativa project (2011–2015) IBiSA (Biology, Health and Agronomics infrastructure) selection of ICAReB platform in 2009 INCA (National Institute for Cancer research): INECOC project, 2009–2011 TOTAL foundation (Afribiota project on Environmental Pediatric Enteropathy, 2016-2020) WHO (for The WHO Human African Trypanosomiasis specimen Bank, 2008–2018, 2019–). Since three years, public-private relationships were proposed and research collaborations accepted with industrial partners, for example the Lyon-Paris ‘Technological Research Institute’ (BioAster) following a national Investissements d’Avenir program launched in 2012.